Home/Filings/4/0001491519-20-000005
4//SEC Filing

Davis Chaim 4

Accession 0001491519-20-000005

CIK 0000896747other

Filed

Jul 1, 8:00 PM ET

Accepted

Jul 2, 5:32 PM ET

Size

5.6 KB

Accession

0001491519-20-000005

Insider Transaction Report

Form 4
Period: 2020-07-01
Davis Chaim
Director
Transactions
  • Award

    Common Shares

    2020-07-01$0.37/sh+35,461$13,121240,561 total
Footnotes (3)
  • [F1]35,461 restricted common shares were issued to Davis in connection with his attendance at three (3) meetings of the Board of Directors. The meetings were held on April 22, 2020 (15,259 shares), May 20, 2020 (16,339 shares) and June 23, 2020 (3,863 shares). This stock issuance is in accordance with the director compensation structure approved by the Company's Board of Directors on March 22, 2018 (as indicted in the Company's Proxy Statement filed with the Commission on April 18, 2018).
  • [F2]The Company uses the average volume weighted price (VWAP) of the Company's common shares for the 10 days preceding each meeting to determine the value of the common shares. The VWAP was $0.1884 for the meeting held on April 22, 2020, $0.176 for the meeting held on May 20, 2020 and $0.7443 for the meeting held on June 23, 2020. This results in an average VWAP of $0.37.
  • [F3]This is the number of securities held directly by Davis. It does not include 2,978,486 common shares in the name of Revach Fund, LP (deemed to be indirectly held by Davis). Davis is the managing member of Revach Group, LLC which operates as the general partner of Revach Fund, LP.

Issuer

AMERICAN BIO MEDICA CORP

CIK 0000896747

Entity typeother

Related Parties

1
  • filerCIK 0001491519

Filing Metadata

Form type
4
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 5:32 PM ET
Size
5.6 KB